Compare NBIX & PR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBIX | PR |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 15.2B |
| IPO Year | 1996 | 2016 |
| Metric | NBIX | PR |
|---|---|---|
| Price | $174.19 | $18.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 19 |
| Target Price | ★ $180.91 | $22.35 |
| AVG Volume (30 Days) | 1.1M | ★ 11.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.96% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 1.91 | 0.05 |
| Revenue | $161,626,000.00 | ★ $5,065,211,000.00 |
| Revenue This Year | $24.73 | $20.94 |
| Revenue Next Year | $13.14 | $7.51 |
| P/E Ratio | ★ $91.24 | $364.00 |
| Revenue Growth | ★ 977.51 | 1.29 |
| 52 Week Low | $122.14 | $11.92 |
| 52 Week High | $174.38 | $22.68 |
| Indicator | NBIX | PR |
|---|---|---|
| Relative Strength Index (RSI) | 67.99 | 38.75 |
| Support Level | $153.96 | $18.04 |
| Resistance Level | N/A | $19.39 |
| Average True Range (ATR) | 4.48 | 0.46 |
| MACD | 0.66 | -0.04 |
| Stochastic Oscillator | 95.56 | 17.11 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Permian Resources Corp is an independent oil and natural gas company focused on generating outsized returns to stakeholders through the responsible acquisition, optimization, and development of oil and liquids-rich natural gas assets. The Company's assets and operations are concentrated in the core of the Permian Basin, and its properties consist of large, contiguous acreage blocks located in West Texas and New Mexico.